Breaking News

BioNxt Begins Drug Absorption Study for Transdermal Rotigotine Patch

Study to assess the relative bioavailability, skin adhesion and skin tolerance of BioNxt's new formulation compared to the name brand product.

BioNxt Solutions Inc. will initiate its comparative drug absorption study for the company’s transdermal (TDS) Rotigotine patch for the treatment of Parkinson’s disease. The company has also commenced the manufacture of clinical samples for use in the study which is planned for early Q2 2023. In addition, BioNxt has finalized its plans for the human bioavailability study to be carried out by a qualified European contract research organization. The comparative study is designe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters